170 related articles for article (PubMed ID: 25854304)
1. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
[TBL] [Abstract][Full Text] [Related]
2. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
3. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP
Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030
[TBL] [Abstract][Full Text] [Related]
4. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
5. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.
Puig-Domingo M; Luque RM; Reverter JL; López-Sánchez LM; Gahete MD; Culler MD; Díaz-Soto G; Lomeña F; Squarcia M; Mate JL; Mora M; Fernández-Cruz L; Vidal O; Alastrué A; Balibrea J; Halperin I; Mauricio D; Castaño JP
PLoS One; 2014; 9(1):e85527. PubMed ID: 24465589
[TBL] [Abstract][Full Text] [Related]
6. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
[TBL] [Abstract][Full Text] [Related]
7. CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.
Werner TA; Forster CM; Dizdar L; Verde PE; Raba K; Schott M; Knoefel WT; Krieg A
Br J Cancer; 2017 Dec; 117(12):1837-1845. PubMed ID: 29112684
[TBL] [Abstract][Full Text] [Related]
8. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
9. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.
Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP
Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin Receptor Splicing Variant
Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
[TBL] [Abstract][Full Text] [Related]
12. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.
Ferreira LB; Eloy C; Pestana A; Lyra J; Moura M; Prazeres H; Tavares C; Sobrinho-Simões M; Gimba E; Soares P
Eur J Endocrinol; 2016 Apr; 174(4):551-61. PubMed ID: 26811408
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.
Zatelli MC; Tagliati F; Taylor JE; Piccin D; Culler MD; degli Uberti EC
Horm Metab Res; 2002 May; 34(5):229-33. PubMed ID: 12063634
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
[TBL] [Abstract][Full Text] [Related]
16. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
[TBL] [Abstract][Full Text] [Related]
18. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis.
Treglia G; Tamburello A; Giovanella L
Hormones (Athens); 2017 Oct; 16(4):362-372. PubMed ID: 29518756
[TBL] [Abstract][Full Text] [Related]
19. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
Del Rio-Moreno M; Alors-Perez E; Borges de Souza P; Prados-Gonzalez ME; CastaÑo JP; Luque RM; Gahete MD
Transl Res; 2019 Sep; 211():147-160. PubMed ID: 30904441
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.
Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
